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Abstract Stuttering is a common but poorly understood
speech disorder. Evidence accumulated over the past
several decades has indicated that genetic factors are
involved, and genetic linkage studies have begun to identify
specific chromosomal loci at which causative genes are
likely to reside. A detailed investigation of one such region
on chromosome 12 has identified mutations in the GNPTAB
gene that are associated with stuttering in large families and
in the general population. Subsequent studies identified
mutations in the functionally related GNPTG and NAGPA
genes. Mutations in these genes disrupt the lysosomal
targeting pathway that generates the Mannose 6-phosphate
signal, which directs a diverse group of enzymes to their
target location in the lysosome of the cell. While mutations
in these three genes can be identified in less than 10% of
cases of familial stuttering, this knowledge allows a variety
of new studies that can help identify the neuropathology
that underlies this disorder.
Keywords Stuttering.Genetics.Linkage.GNPTAB.
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Introduction
Stuttering is a speech disorder characterized by involuntary
repetitions or prolongations of words or syllables, or by
involuntary interruptions in the flow of speech, known as
blocks (Bloodstein and Ratner 2008). The disorder typically
arises in children at age 3–4 years, where it is common,
affecting up to 20% of all children. In 75–80% of these
children, the disorder spontaneously resolves. However, in
the remaining fraction, the disorder persists into adoles-
cence and adulthood, where it is difficult to treat. The
disorder preferentially affects males. At the typical age of
onset, males slightly outnumber females, and with time,
females tend to recover more frequently than males, which
leaves a male/female ratio of approximately 4:1 in
persistent stuttering. While the disorder has been clini-
cally well described for millennia, its underlying causes
have been unknown. A remarkable array of potential
causes of stuttering have been hypothesized, however the
lack of clear data supporting any of these suggested
causes has hampered the development of more effective
speech therapies.
Although specific causes of stuttering long remained
obscure, it was clear that genetic factors play a role in the
disorder. Evidence supporting this has come from numerous
independent twin studies (Andrews et al. 1991; Howie
1981; Felsenfeld et al. 2000; Ooki 2005; Dworzynski et al.
2007), from adoption studies (Felsenfeld and Plomin 1997;
Bloodstein 2006), and from studies of large families in
which there are many cases of stuttering (MacFarlane et al.
1991). However, although a clear role for genetic factors
was established, a more precise understanding of the nature
of these factors has been elusive. Although the disorder
predominantly affects males, transmission from fathers to
sons is commonly observed, which rules out X-linked
inheritance. In addition, there have been conflicting reports
regarding other possible modes of inheritance of stuttering
(e.g., dominant or recessive), and there has been conflicting
evidence for the presence of a single major gene causing the
disorder in families.
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linkage study, in which genetic markers positioned along
the length of each human chromosome are tested for co-
inheritance (i.e., linkage) with the disorder as it is passed
down through families. Because the chromosomal locations
of each of the markers tested is known, the observation of
linkage with a particular marker or markers identifies the
location of the causative gene(s) in those families.
However, the lack of Mendelian inheritance of stuttering
in families rendered such studies, which traditionally rely
on a clear model of inheritance, unfeasible. The develop-
ment of so-called model-free or non-parametric methods for
the statistical analysis of linkage data addressed this
problem, and a number genome-wide linkage studies of
stuttering have now been published (Shugart et al. 2004;
Wittke-Thompson et al. 2007; Suresh et al. 2006). In
general the results of these studies have been somewhat
disappointing, because they have predominantly generated
linkage scores of marginal statistical significance. More-
over, linkage locations observed in one study were not
replicated in others.
To address this problem, we turned to families with
many cases of stuttering from highly consanguineous
populations. Such inbred populations have traditionally
been advantageous for studies of genetic disorders, and the
incidence of recessive disorders in particular is highly
elevated compared to that in outbred populations. Although
stuttering does not in general display a recessive or any
other clear Mendelian inheritance pattern, we hypothesized
that such consanguineous families would enable more
effective linkage studies of stuttering. We initially recruited
44 consanguineous families, each with multiple individuals
who stutter, from the city of Lahore, Pakistan and
surrounding areas. Other speech-language disorders or
other neurological phenotypes were not reported by the
families, and not observed by the local evaluating speech-
language pathologist. The Stuttering Severity Instrument,
3rd Edition, was used to characterize stuttering in these
families.
We performed a linkage study that enrolled 44 families
from Pakistan, each containing multiple cases of stuttering,
and performed a genome-wide search for linkage. The
results of this study were clear. We observed a strong
linkage signal on the long arm of chromosome 12 (Riaz et
al. 2005). Our subsequent studies have focused on
identifying the causative genetic variation that resides in
this region of chromosome 12.
Analysis of genes on chromosome 12
The region of chromosome 12 identified in our linkage
study spanned more than 10 million bp of DNA and
contained 87 known and predicted genes. Given the
daunting task of evaluating this large candidate region, plus
the complex inheritance pattern observed for stuttering, we
hypothesized that analysis of a single large family provided
thebestchancesofidentifyingauniquecausalgeneticvariant.
We chose one of the largest families from our Pakistani
linkage study, family PKST 72 (Fig. 1), for this purpose. We
initially performed a customized comparative genomic array
hybridization study using CGH 385 K Array (NimbleGen) to
look for large-scale genetic lesions (such as chromosomal
deletions or inversions) that were shared only by the affected
members of family PKST 72. No such variants were
identified. We then undertook systematic DNA sequencing
of 45 of the 87 genes in this region in PKST 72 family
members. This allowed us to identify a number of genetic
variants in affected members of PKST 72; however, most of
these variants were commonly observed in the normal
Pakistani population, indicating that they were non-
pathogenic natural polymorphisms.
The variant that co-segregated most closely with stuttering
in PKST 72 was an apparent mutation that substituted an
Fig. 1 Pedigree structure
of Pakistani stuttering family
PKST 72. Filled blocks and
circles denote affected family
members, open blocks and
circles denote the
unaffected ones
J Neurodevelop Disord (2011) 3:374–380 375adenine residue for the normal guanine residue that exists at
position 3598 in the coding sequence of a gene designated
GNPTAB (Kang et al. 2010). This mutation predicted the
substitution of a positively charged lysine for the normal,
negatively charged glutamic acid present at amino acid
position 1200 in the GNPTAB protein. A comparison of the
sequence of the GNPTAB gene in other species revealed that
the glutamic acid at residue 1200 was conserved in the
GNPTAB protein in all species known, suggesting that a
glutamic acid is necessary for an important functional role at
this position in the protein. An initial screen of 96 normal
Pakistani control subjects showed that only one carried a
lysine at this position, and no other amino acids other than
glutamic acid were observed at this position. Sequencing a
single representative affected individual from each of the
other 43 families included in the genome-wide linkage study
of Riaz et al. (2005) revealed the lysine mutation at position
1200 in three additional Pakistani stuttering families, PKST
05, 25, and 41. The appearance of the same mutation in the
same gene in a number of families, independently ascer-
tained solely on the basis of familial stuttering, was a strong
piece of evidence favoring the hypothesis that mutations in
this gene cause stuttering. In these families, affected individ-
uals carried either one or two copies of this mutation. This
observation is consistent with the complex, non-Mendelian
inheritance pattern well known to occur in stuttering families
(Kidd et al. 1981; Cox et al. 1984).
We then examined the GNPTAB gene more fully in 316
unrelated individuals who stutter and in 276 unrelated
neurologically normal controls. Additional mutations at
other sites in this gene were identified in our cases, but no
variants were observed in any of our controls (Table 1). In
human gene finding studies, the identification of different
mutations in the same gene in different families with the
same disorder constitutes substantial proof that the disease
gene has been correctly identified. Thus, our finding of
additional mutations in the GNPTAB gene in unrelated
familial cases of stuttering added significant additional
support to our hypothesis that mutations in GNPTAB cause
stuttering.
The GNPTAB gene and the lysosomal enzyme-targeting
pathway
The GNPTAB gene encodes a portion of the enzyme
GlcNAc-phosphotransferase (EC 2.7.8.17). This enzyme
acts in the first step of the so-called lysosomal enzyme-
targeting pathway. This pathway functions to generate the
mannose-6-phosphate targeting signal that serves as a
marker, recognized by the mannose-6-phosphate receptors,
that direct a large group of degradative hydrolases (~60) to
the lysosome (Reitman and Kornfeld 1981) (Fig. 2). The
GNPTAB gene encodes a single polypeptide that is
subsequently cleaved to generate the α and β subunits,
which together constitute the catalytic subunits of the
GlcNAc-phosphotransferase enzyme. The holoenzyme also
contains a third subunit, designated γ, which serves the
function of substrate recognition. The γ subunit is encoded
by the GNPTG gene. This gene thus became a functional
candidate gene for stuttering.
Examination of the sequence of the GNPTG gene
revealed a number of mutations, all at amino acid positions
evolutionarily conserved within the encoded protein, in
Table 1 Mutations found in the GNPTAB, GNPTG and NAGPA genes in stuttering (Kang et al. 2010)
Mutation Amino acid change Number of mutation carriers
Pakistani stutterers (N=123) Pakistani controls
(N=96)
North American
stutterers (N=316)
North American
controls (N=276)
GNPTAB
Exon9 c.961A>G p.Ser321Gly 1 0 0 0
Exon11 c.1363 G>T p.Ala455Ser 0 0 2 0
Exon13 c.1875 C>G p.Phe624Leu 1 0 0 0
Exon19 c.3598 G>A p.Glu1200Lys 7 1 2 0
GNPTG
Exon1 c.11_19dup p.Leu 5_Arg7dup 0 0 1 0
Exon2 c.74 C>A p.Ala25Glu 0 0 2 0
Exon9 c.688 C>G p.Leu230Val 0 0 1 0
NAGPA
Exon2 c.252 C>G p.His84Gln 0 0 2 0
Exon6 c.982 C>T p.Arg328Cys 0 0 5 0
Exon10 c.1538_1553del p.Phe513SerfsX113 0 0 1 0
376 J Neurodevelop Disord (2011) 3:374–380individuals who stutter (Table 1). None of these variants
were observed in the GNPTG gene of 276 neurologically
normal control subjects or in databases of normal human
genetic variants, such as dbSNP (http://www.ncbi.nlm.nih.
gov/projects/SNP/).
The lysosomal enzyme-targeting pathway has two
steps. The first is carried out by the GNPTAB/G
phosphotransferase enzyme. The second step is carried
out by the enzyme N-acetylglucosamine-1-phosphodiester
alpha N-acetylglucosaminidase (EC 3.1.4.45), encoded by
the NAGPA gene. This enzyme is commonly referred to as
the Uncovering Enzyme (UCE), because it functions to
remove the terminal GlcNAc residue, exposing the
mannose-linked phosphate (Fig. 2)t h a ts e r v e sa st h e
ultimate targeting signal. The NAGPA gene thus also
became a candidate gene for stuttering. Sequencing this
gene quickly revealed a number of different mutations in
stuttering cases, none of which occurred in normal
controls (Table 1). One of these mutations (encoding a
cysteine in place of the normal arginine at position 328 in
this protein) was observed in five unrelated stutters,
suggesting that it may be a commonly occurring mutation
in stuttering.
Together, our data provide a strong argument for the
involvement of mutations in the lysosomal enzyme-
targeting pathway in stuttering. The mutations we observed
were generally uncommon in the stuttering population. In
aggregate, a mutation was observed in one of these three
genes in approximately 8% of our unrelated cases of
familial stuttering. However, given the relatively high
frequency of persistent stuttering in the general population
(estimated to be as high as 1%), this frequency could
represent a substantial number of cases attributable to such
mutations, perhaps tens of thousands of cases in the United
States alone.
Lysosomal targeting disorders in humans —
the mucolipidoses
Mutations in the genes encoding the lysosomal enzyme-
targeting pathway in humans are well studied. Mutations in
GNPTAB cause mucolipidosis type II (MLII, formerly
known as I-cell disease, MIM#252500) or type IIIA
(MLIIIA, formerly known as pseudo-Hurler polydystrophy,
MIM#252600) (Kudo et al. 2006), while mutations in
GNPTG cause mucolipidosis type IIIc (MLIIIc, formerly
known as variant pseudo-Hurler polydystrophy,
MIM#252605) (Raas-Rothschild et al. 2000). ML II and
IIIA are rare lysosomal storage disorders characterized by
pathology in many tissues, including the skeletal system,
connective tissues, brain, liver and spleen. A detailed
clinical examination of four stuttering subjects containing
mutations in these genes revealed no symptoms associated
with ML II or III, and other than moderate to severe
persistent stuttering, all subjects were neurologically
normal by medical examination. One possible explana-
tion for this discrepancy is that ML II and III are
typically associated with complete or near complete loss-
of-function mutations, such as deletions or stop codons,
Fig. 2 Two-steps adding mannose-6-phosphate markers on lysosomal
enzymes. In the first step, GlcNAc-phosphotransferase (GNPTAB/G)
transfer GlcNAc-1-phosphate from UDP-GlcNAc to terminal mannose
residues of N-linked glycans on enzymes destined to the lysosome. In
the second step, N-acetylglucosamine-1-phosphodiester-alpha-N-ace-
tylglucosaminidase (NAGPA), also known as the uncovering enzyme,
cleaves off the GlcNAc residue, thereby exposing mannose-6-
phosphate (circled). Enzymes with this recognition marker are then
transported from Golgi to the lysosome
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ing are mis-sense mutations which may not abolish the
functioning of these enzymes. Biochemical functional
studies of the enzymes that carry mutations we’ve found
in stuttering subjects will be an important adjunct to our
genetic findings thus far. An interesting observation in
children with ML II is that although this severe disease is
fatal in the first decade of life, even the children who
survive the longest fail to gain the ability to speak
(Otomo et al. 2009).
No human disorder has previously been associated with
mutations in the NAGPA gene. This has been puzzling, as
such mutations might be expected to cause symptoms
similar to mucolipidosis types II and III. We hypothesize
that the predominant manifestation of mutations in the
NAGPA gene is persistent nonsyndromal stuttering.
Other potential mutations affecting lysosomal
function in stuttering
Many different chromosomal locations have generated
suggestive evidence for linkage in family studies of
stuttering (Shugart et al. 2004; Wittke-Thompson et al.
2007; Suresh et al. 2006). Given our results implicating
mutations affecting lysosomal function in stuttering, it is
reasonable to hypothesize that mutations in other genes
encoding lysosomal functions may contribute to this
disorder. Although several such genes reside near a
previously suggested linkage signal for stuttering, to date
we have not yet identified mutations in any of these genes
in our stuttering population.
Population genetics of stuttering
Many of the mutations in these three genes were observed
only once in our stuttering cases, suggesting that they are
rare. However two mutations, the substitution of a lysine at
position 1200 in GNPTAB and the substitution of a cysteine
at position 328 in NAGPA, were repeatedly observed in
apparently unrelated individuals. The lysine variant at
position 1200 was observed in the affected members of
four ostensibly unrelated Pakistani families (PKST 5, 25,
41, and 72) as well as in three unrelated individual cases.
The cysteine variant at position 328 in NAGPA has now
been observed in five unrelated individuals.
There are two ways in which a mutation comes to be
commonly observed in apparently unrelated individuals.
The first is due to a so-called mutation hotspot, in which
new mutations repeatedly arise at the same position in the
same gene. The second explanation is a founder mutation,
which occurred once in the distant past and has been passed
down to the individuals who carry it today. Such individuals
are thus actually distantly related to each other through the
common ancestor in whom the mutation arose. These two
possibilities can be distinguished by examining the DNA
sequence of the chromosomes surrounding the mutation in
different individuals.Repeated mutations typically arise atthe
same site on the same chromosome in different individuals.
These chromosomes are distinguishably different between
different individuals, and the DNA sequence surrounding the
mutation shows occasional variant sites that are different in
each mutation-carrying chromosome. Founder mutations
typically still carry some of the chromosome on which they
arose, leading to a so-called conserved haplotype of DNA
sequence variants surrounding the mutation in different
individuals (Drayna 2005). We have not yet identified
enough cases of the cysteine mutation at position 328 in
NAGPA for a statistically significant analysis. However, we
have observed a total of 14 chromosomes carrying the lysine
mutation at position 1200 in GNPTAB, sufficient for an
initial study of this question.
All 14 chromosomes containing this mutation shared a
common haplotype of variants in the surrounding
chromosomal DNA, indicating that it is a founder
mutation. The length of the shared haplotype can be
used to estimate the age of this mutation. In this case the
estimate is subject to wide error due to the small sample
size, but it is clear that the mutation is quite old, with a
most likely estimate of ~570 generations, or about
14,000 years (Fedyna et al. 2011). It is noteworthy that
all individuals carrying this mutation have their familyorigins
ineitherPakistanorIndia.Alimitedgeographicdistributionis
common for many founder mutations, further supporting our
conclusion regarding the origin of this mutation.
Neuropathology of stuttering
How do mis-sense mutations in genes encoding the
lysosomal enzyme-targeting pathway specifically cause
stuttering? At present, we do not know. The lysosomal
enzyme-targeting pathway exists, and the GNPTAB/G and
Fig. 3 Pedigree structure of Pakistani stuttering family PKST 77.
Filled blocks and circles denote affected family members, open blocks
and circles denote the unaffected ones
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(Kornfeld et al. 1999). However, we hypothesize that
mutations in these genes generate a metabolic defect in a
class of neurons uniquely dedicated to speech. At this time,
we believe such neurons are unique to speech because of
the lack of other detectable neurologic symptoms in the
individuals carrying these mutations that we have evaluated
to date. Consistent with this hypothesis is the fact that
lysosomal storage disorders frequently display a striking
specificity in the organs, or the subtissues within organs,
that are affected (Kornfeld and Sly 2010). The future goals
of our research are to identify the cells within the brain that
are affected by these mutations, to determine the normal
function of these cells, to trace their connections within the
central and peripheral nervous system, and to determine
how the function of these cells is altered by the stuttering
mutations we have found.
Finding additional stuttering genes
Our findings to date can explain less than 10% of familial
stuttering. Our goal has been to apply our genetic approach
to identifying the underlying genes in other cases of this
disorder. To this end, we have recently enrolled an
additional set of highly consanguineous families in
Pakistan, each having multiple individuals affected with
persistent stuttering. A genetic linkage study of one of
these families, designated PKST 77, has identified a
locus on chromosome 3 that shows strong evidence for
linkage to stuttering (Fig. 3) (Raza et al. 2010). No gene
or linkage signal for stuttering has previously been
s u g g e s t e dt or e s i d ea tt h i sl ocus, indicating that the
identification of this gene is likely to provide new insights
into the pathology of persistent stuttering.
Future research opportunities
The finding of mutations associated with stuttering has
opened a number of possible new avenues for research. One
longstanding question in speech-language pathology has
been why stuttering therapy can have very different
outcomes in different individuals. One possibility is that
such outcomes are influenced by different genetic muta-
tions carried by different individuals. Because we now have
genetic mutations that we can test, it becomes possible to
address this question.
Another exciting avenue of research is based on the large
body of knowledge that exists on the biochemistry and cell
biology of the GNPTAB/G and NAGPA enzymes, which is
available due to decades of careful medical research on the
mucolipidoses. Why do some mutations in these genes
cause mucolipidosis, a fatal multi-organ system disease,
while other mutations in the same genes cause only
stuttering? What are the enzymatic and cell biological
consequences of these stuttering mutations, and how can
they help elucidate the neuropathology underlying this
disorder? The well-established biochemical assays for
these enzymes (Reitman and Kornfeld 1981;V a r k ia n d
Kornfeld 1981) hold the promise of answering these
questions in some detail.
Finally, it is clear from comparative genomic analysis
studies that humans and other mammalian species share the
vast majority of their genes. It is clear that although speech
and language are unique to humans, these abilities are built
upon structures and functions that are encoded by genes
that are not unique to humans. This suggests that studies in
model organisms may be useful in understanding stuttering.
Mice carrying complete loss of function mutations (knock-out
mice) have been engineered for the GNPTAB and GNPTG
genes. These mice display symptoms similar to human
mucolipodiosis and die at an early age (Gelfman et al.
2007; Vogel et al. 2009). Therefore, it will be necessary to
engineer the equivalent of human stuttering mutations in
these genes (creating knock-in mice) to generate plausible
mouse models of human stuttering. While mouse vocal-
izations are extremely rich (Holy and Guo 2005), they
remain poorly characterized, partly because most of them are
ultrasonic and not accessible to analysis without sophisticated
acoustical methods. However, the observation of altered
vocalization in a mouse carrying a human stuttering mutation
would open a wide array of studies that could exploit the
unparalleled genetic methods available in this species. In
addition, the availability of such mice will allow a search for
other neurological deficits that may manifest themselves in
such mice, and will facilitate neuropathology studies that
could identify specific degenerative processes in the mouse
brain. Although genetic studies of stuttering are in their
infancy, we believe such studies hold the promise of
significant advances in our understanding of this common
speech disorder at the molecular and cellular level.
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